BioWave,  Vol. 25 No. 4
연구실 홈페이지

 We are ImmunoBiopharmaceuticals Laboratory, performing an interdisciplinary and cutting-edge research at Inha University. Our team seeks to understand basic principle and underlying mechanism of disease to develop new therapeutic approach.

 Son Laboratory is interested in elucidating how biomaterials interact with biological environment and coordinate biological/immunological functions, in order to better deal with the complexity of disease progression. As disease is getting complicated, our team seeks to design, construct, and evaluate an unique, sophisticated bio- and nano-systems capable of interacting with disease microenvironment to promote the precise action of biopharmaceuticals including genes, vaccine components, and antibodies. With solid ground on PI's diverse research and educational backgrounds covering biomaterials, bioengineering, micro- and nanotechnologies, immune-oncology and gene therapy, our team aims to develop new and multidisciplinary biomaterials-based tools and principles to modulate immune responses and promote the precise action of biopharmaceuticals for cancer, infectious disease, and autoimmune disease. The proposed studies will not only contribute to understanding of largely unexplored interdisciplinary research areas of material science, immunology and cancer biology, but also promote clinical translation of new immunotherapies.

  Sejin Son, Ph.D
  Associate Professor, Department of Biological Sciences, Inha University

   2017-2021 Assistant Research Scientist, Department of Pharmaceutical Sciences and Biomedical
    Engineering, University of Michigan
   2014-2017 Postdoctoral Fellow, Harvard Medical School/Brigham Women's Hospital
   2012-2014 Postdoctoral Fellow, Biomedical Research Institute, Korea Institute of Science and Technology
   2008-2012 Ph.D., Chemistry, Pohang University of Science and Technology (POSTECH)
   2006-2008 M.S., Molecular Science and Technology, Ajou University
   2001-2006 B.S., Applied Chemistry and Biotechnology, Ajou University

 1. Cancer research

 Among many other reasons, a root reason of current cancer therapy failure is based on genetic mutations acquired in healthy cells that sequentially make changes in genome. Many mutations are acquired in a random fashion and the random nature of this mutation has two consequences. One is that every patient has a different cancer. And the second consequence is that every tumor cell within a cancer is a different entity. These cancer cells in advanced stage are at least 1 billion different cells. Even further, they are able to adapt and resist to the treatment and metastasize. The way we treat cancer today, however, ignore this complexity and is not able to deal with the plasticity of the cancer.

 So the next question is then, there a solution to deal with this complexity?

Neoantigen cancer vaccine will be a first, true sense of personalized cancer treatment

 Now we are entering new era of cancer medicine into the true sense of personalized precision cancer medicine from conventional approach so called one-size-fit all medicine and targeted therapy to stratified patient to improve therapeutic outcome. Thanks to deep sequencing, now we are able to identify patient-specific cancer-neoantigens, that are ready to be given to patient in time about 6-10 weeks. In 2017, the two research groups from the US and German reported the results of the first human clinical trials of neoantigen-based cancer vaccines, one used peptide-based and the other used mRNA-based vaccines. The therapeutic outcome was promising despite the need for improvement, showing feasibility, safety and immunotherapeutic activity of targeting individual tumor mutations. And now the field reasonably expect that the neoantigen cancer vaccine may become the ever first true personalized treatment for cancer.

 Son laboratory aims to develop unique and highly multidisciplinary cancer engineering strategy that can better deal with the complexity of tumor microenvironment (TME) for cancer precision medicine.
  1. Personalized cacner vaccine technology
  2. Gene therapy to up and down regulate multiple pathways of immune suppressive mechanisms within tumor microenvironment
  3. Ultrasound technology to physically disrupt tumor ECMs and/or provok immune response

 2. Emerging mRNA therapeutics

 Son laboratory has expertise in developing versatile gene delivery systems. We leverage the delivery tools to address a range of technical challenges that RNA therapeutics have in the clinic.
  1. mRNA-based vaccine development
  2. Therapeutic antibody-encoding mRNA for cancer immunotherapy
  3. mRNA therapeutics for undruggable target

 3. In vivo immune cell engineering

 Son laboratory aims to develop various immune cell subset engineering strategies for cancer, inflammation, and immune tolerance.
  1. Dendritic cells (DCs) targeting for CD8 and CD4 T cells targeting vaccine development
  2. Macrophage engineering to repolarize tumor associated macrophages (TAMs)
  3. Neutrophils (granulocytes) engineering for cancer and inflammation


Selected publications

41. Jutaek Nam*, April Kim*, May Phoo, Jinsung Ahn, Soohong Lee, James J. Moon#, Sejin Son#, Pattern Recognition Receptors (PRRs) Targeting Strategy by Polysaccharide Engineering to Modulate Innate and Adaptive Immune Response,

40. Isra Rana, Jaeeun Oh, Juwon Baig, Jung Hyun Moon, Sejin Son#, Jutaek Nam#, Nanocarriers for cancer nano-immunotherapy, In revision, Drug Delivery and Translational Research

39. Sejin Son*# Jutaek Nam*, April S. Kim, Jinsung Ahn, Kyung Soo Park, May Thazin Phoo, Brett Sherren, Weiping Zou, Soo-Hong Lee, Omid C. Farokhzad, Jinjun Shi, James J. Moon#, Mannan-based Nanocapsules for Induction of Th17-mediated Anti-tumor Immune Response, Accepted, Nature Biomedical Engineering.

38. Nam J*, Son S*, Park K, Moon JJ, Photothermal therapy combined with neoantigen cancer vaccination for effective immunotherapy against large established tumors and distant metastasis, 2021, 2100093, Advanced Therapeutics.

37. Park K, Nam J, Son S, Moon JJ, Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells, 2021, Biomaterials, 274, 120844, Biomaterials.

36. Park K, Bazzill J, Son S, Nam J, Shin SW, Stuckey J, Meagher J, Song J, Montefiori DC, LaBranche CC, Smith J, Xu J, and Moon JJ, Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2, 2021, 330, 529-539, Journal of Controlled Release.

35. Nam J*, Son S*, Park K, Moon JJ, Modularly programmable nanoparticle vaccine based on polyethyleneimine for personalized cancer immunotherapy, 2021, 8 (5), 2002577, Advanced Science.

34. Scheetz L, Kadiyala P, Sun X, Son S, Najafabadi A, Aikins M, Lowenstein P, Schwendeman A, Castro M, and Moon JJ. Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas, 26, 16, 4369-4380, 2020, Clinical Cancer Research.

33. Son S*, Nam J*, Zenkov I, Ochyl LJ, Xu Y, Scheetz L, Shi J, Farokhzad OC# Moon JJ#. Sugar-Nanocapsules imprinted with Microbial Molecular Patterns for mRNA Vaccination, 2020, 20, 3, 1499-1509, Nano Letters.

32. Nam J*, Son S*, Park KS, Moon JJ. Cancer nanomedicine for the new era of combination cancer therapy, 4 (6), 398-414, 2019, Nature Review Materials.

31. Kuai R*, Yuan W*, Son S, Nam J, Xu Y, Fan Y, Schwendeman A, and Moon JJ. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy, 4, eaao1736, 2018, Science Advances.

30. Nam J*, Son S*, Ochyl LJ, Kuai R, Schwendeman A, Moon JJ. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer, 9, 1074, 2018, Nature Communication.



 지도교수: 손세진 교수

   (2022년 현재)
 Master-PhD joint program : 박범준
 Master student : 진위현
 Internship student : 이주비, 백주원, 문정현, 오재은, 김유빈
 Contact :

* 본 정보는 해당 대학/연구실에서 제공하는 자료를 바탕으로 구성된 내용으로, BRIC에서 작성한 정보가 아님을 밝힙니다.
* 소개된 내용에서 중요하게 판단되는 부분은 해당 기관에 추가적으로 사실 확인 작업을 하시길 부탁드립니다.
* 내용의 업데이트 또는 변경을 원하시면 관리자(에게 연락 바랍니다.
등록일 2022.11.21
HOME   |   이용약관   |   개인정보처리방침